The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?
Open accessAbstract
There is growing interest in the various mechanisms that regulate chromatin remodeling, including modulation of histone deacetylase (HDAC) activities. Competitive HDAC inhibitors disrupt the cell cycle and/or induce apoptosis via de-repression of genes such as P21 and BAX, and cancer cells appear to be more sensitive than non-transformed cells to trichostatin A and related HDAC inhibitory compounds. This apparent selectivity of action in cancer cells makes HDAC inhibitors an attractive avenue for drug development. However, in the search for potent HDAC inhibitors with cancer therapeutic potential there has been a tendency to overlook or dismiss weak ligands that could prove effective in cancer prevention, including agents present in the human diet. Recent reports have described butyrate, diallyl disulfide and sulforaphane as HDAC inhibitors, and many other dietary agents will be probably discovered to attenuate HDAC activity. Here we discuss 'pharmacologic' agents that potently de-repress gene expression (e.g. during therapeutic intervention) versus dietary HDAC inhibitors that, as weak ligands, might subtly regulate the expression of genes involved in cell growth and apoptosis. An important question is the extent to which dietary HDAC inhibitors, and other dietary agents that affect gene expression via chromatin remodeling, modulate the expression of genes such as P21 and BAX so that cells can respond most effectively to external stimuli and toxic insults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Mechanism of Human SIRT1 Activation by Resveratrol
Borra, M. T., Smith, B. C., & Denu, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501250200 · Cited by 1,065
The promise of retinoids to fight against cancer
Altucci, L., & Gronemeyer, H. (2001) · Nature Reviews Cancer · doi:10.1038/35106036 · Cited by 773
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412
New insight into butyrate metabolism
Knudsen, K. E. B., Serena, A., Canibe, N., & Juntunen, K. S. (2003) · Proceedings of the Nutrition Society · doi:10.1079/pns2002212 · Cited by 134
Cited by
Review article: the role of butyrate on colonic function
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. J., & BRUMMER, R. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03562.x · Cited by 2,721
The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon
Donohoe, D. R., Garge, N., Zhang, X., Sun, W., O'Connell, T. M., Bunger, M. K., & Bultman, S. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.018 · Cited by 2,003
“Butyrate is noteworthy because it is a histone deacetylase (HDAC) inhibitor that regulates gene expression and also serves as the primary energy source for the colonic epithelium (Boffa et al., 1978; Candido et al., 1978; Dashwood et al., 2006; Garcea and Alberts, 1980; Roediger, 1980, 1982).”
Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis
HIGDON, J., DELAGE, B., WILLIAMS, D., & DASHWOOD, R. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.01.009 · Cited by 1,039
Self-citationChild Health, Developmental Plasticity, and Epigenetic Programming
Hochberg, Z., Feil, R., Constancia, M., Fraga, M., Junien, C., Carel, J.-C., Boileau, P., Le Bouc, Y., Deal, C. L., Lillycrop, K., et al. (2011) · Endocrine Reviews · doi:10.1210/er.2009-0039 · Cited by 627
Ghaisas, S., Maher, J., & Kanthasamy, A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.012 · Cited by 521
Metadata
- Authors
- Dashwood, R. H., Myzak, M. C., & Ho, E.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-19
- Volume
- 27
- Issue
- 2
- Pages
- 344-349
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2153601430
- Cited by
- 186
- References
- 5
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? https://app.cochat.ai/papers/10.1093/carcin/bgi253
- The paper
- Dashwood, R. H., Myzak, M. C., & Ho, E. (2006). Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis. https://doi.org/10.1093/carcin/bgi253
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.